查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806394

HIV/AIDS 診斷市場（按檢測類型、產品類型、檢測方法、最終用戶和應用）—2025-2030 年全球預測

HIV or AIDS Diagnostics Market by Test Type, Type of Product, Testing Method, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年愛滋病毒/愛滋病診斷市場價值將達到 24.5 億美元，2025 年將成長至 26 億美元，複合年成長率為 6.34%，到 2030 年將達到 35.4 億美元。

主要市場統計數據
基準年2024年 24.5億美元
預計2025年 26億美元
預測年份 2030 35.4億美元
複合年成長率（%） 6.34%

HIV/AIDS 診斷解決方案的快速發展改善了早期發現和患者治療效果，並重新定義了策略夥伴關係

近年來，在分子生物學、數位健康以及對病毒病理生理學的深入了解推動下，愛滋病毒/愛滋病診斷領域發生了重大變化。如今的診斷生態系統已遠遠超越傳統實驗室，融合了快速即時診斷平台、居家自測解決方案以及為臨床醫生提供即時洞察的整合數據分析。早期精準檢測仍然是有效患者管理的基礎，多重抗體檢測和下一代病毒載量技術等進展正在縮小靈敏度和周轉時間的關鍵差距。此外，診斷研發人員、公共衛生機構和社區組織之間的合作正在擴展檢測服務，以確保服務匱乏的人群能夠公平地獲得檢測服務。

新的即時診斷技術和綜合護理模式正在改變全球愛滋病毒/愛滋病診斷格局

HIV/AIDS 診斷領域的創新正以前所未有的速度發展，這得益於新型即時診斷技術和整合護理模式，這些模式解決了長期以來在獲取和速度方面面臨的挑戰。雖然實驗室平台在病毒量量化方面依然擁有無與倫比的靈敏度，但可攜式免疫檢測測定儀和核酸擴增設備的普及使臨床醫生即使在偏遠地區也能現場獲取結果。同時，自測檢測套組正在賦能個人，使其能夠積極參與自身健康，減少污名化，並擴大傳統基礎設施有限的社區的檢測覆蓋率。

評估美國關稅對 2025 年愛滋病毒/愛滋病診斷供應鏈、定價和全球市場動態的累積影響

2025年美國關稅為愛滋病毒/愛滋病診斷供應鏈帶來了新的動態，影響了成本結構、籌資策略和區域夥伴關係。對原產於受影響地區的試劑和耗材徵收關稅，促使一些供應商重新評估其採購，並考慮區域製造地。因此，製造商正在加快步伐，建立關鍵檢測零件的本地生產設施，以減少對跨境運輸的依賴，並降低未來關稅波動的影響。

揭示愛滋病毒/愛滋病診斷中測試類型、產品、測試方法、最終用戶和應用方面的關鍵市場細分洞察

當全面考慮定義 HIV/AIDS 診斷市場的各種測試類型、產品、調查方法、最終用戶設定和應用領域時，就會對 HIV/AIDS 診斷有細緻的了解。抗體檢測仍然是基礎，包括酵素結合免疫吸附檢測法、快速免疫層析和確認性西方墨點法，每種方法都針對不同的操作需求和靈敏度要求。利用流式細胞技術、基於 PCR 的擴增和創新的微流體方法，CD4 細胞計數和病毒量定量對於疾病分期和治療監測仍然至關重要。同時，從專門的酵素基材到冷凍乾燥 PCR 預混液等消耗品和試劑，以及將樣本製備、擴增和檢測整合到簡化的工作流程中的儀器和套件，正在塑造診斷格局。

分析影響美洲、歐洲、中東和非洲以及亞太地區愛滋病毒/愛滋病診斷成長和創新的關鍵區域動態

美洲地區由成熟的北美醫療保健體系和新興的拉丁美洲市場組成，該地區正大力推廣先進的分子檢測技術，同時公共衛生篩檢舉措也不斷擴展。該地區的利害關係人受益相關人員強力的法律規範、大量的研發投入以及政府與私人實驗室之間的合作，從而促進了早期檢測宣傳活動和治療監測計畫的開展。相較之下，歐洲、中東和非洲地區的需求則呈現出多樣化的特徵：高所得國家正在部署次世代定序儀進行抗藥性分析，而低收入地區則利用照護現場和自我檢測解決方案來克服基礎設施限制，並惠及服務不足的社區。

介紹推動愛滋病毒/愛滋病診斷領域創新、夥伴關係和策略舉措的領先產業參與者

在策略性收購、突破性創新和廣泛分銷網路的推動下，領先的診斷公司持續塑造著愛滋病毒/愛滋病檢測格局。全球醫療科技公司正透過與專注於快速檢測開發和數位化互聯解決方案的生物科技新興企業建立有針對性的合作夥伴關係，強化其產品組合。這些夥伴關係關係催生了將血清學、細胞學和分子檢測與雲端基礎彙報相結合的整合平台，滿足了實驗室準確性和照護現場便利性的雙重需求。

為行業領導者提供可行的建議，以應對診斷領域的監管變化、技術進步和競爭壓力

為了應對愛滋病毒/愛滋病診斷技術的複雜演變，產業領導者應優先考慮供應鏈多元化，建立區域製造聯盟並制定緊急採購通訊協定。採用模組化儀器設計和靈活的試劑格式，可以快速回應關稅波動和監管變化。同時，將人工智慧主導的分析技術融入診斷工作流程，可增強預測能力，支援臨床決策，並最佳化疾病監測工作。在此技術基礎上，鼓勵利害關係人與遠端醫療服務提供相關人員和社區組織建立夥伴關係，以擴大和改善檢測結果呈陽性後的醫療服務可近性。

概述一種利用一手資料和二手資料對愛滋病毒/愛滋病診斷市場進行全面分析的穩健調查方法

這項研究採用了嚴謹的多層次方法，結合了對關鍵意見領袖、實驗室主任、監管專家和重點地區採購負責人的初步訪談。二次研究則廣泛研究了同行評審日誌、技術白皮書、專利申請、監管資料庫和公共衛生出版物，以了解最新的創新和政策發展。數據經過三角測量，以檢驗趨勢、識別新興應用，並協調專有資訊和開放原始碼資訊之間的差異。

摘要關鍵發現和策略意義，為不斷發展的愛滋病毒/愛滋病診斷生態系統中的相關人員提供指導

總而言之，HIV/AIDS 診斷領域正處於一個關鍵的十字路口，其特點是技術創新加速、監管格局不斷變化以及對分散檢測的重視。先進的即時診斷平台、數位健康整合和模組化試劑的相互作用正在重新定義臨床路徑，並為患者提供及時、可操作的結果。基於基礎設施成熟度、政策框架和公私合作夥伴關係的地區差異凸顯了製定客製化策略的必要性，以同時滿足大量的篩檢需求和專業的監測要求。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 照護現場愛滋病毒自我檢測套組與行動醫療應用程式結合，可改善患者與照護之間的互動
  • 在分散環境中採用基於 CRISPR 的診斷方法進行快速、超靈敏的 HIV 病毒量定量
  • 第四代多重抗原抗體檢測對早期發現急性HIV感染的影響
  • 擴展的多重 PCR 面板可在單次測試中同時檢測 HIV、C型肝炎和結核病合併感染
  • 基於人工智慧的影像分析在流式細胞技術中的新用途，用於在 HIV 監測中自動計數 CD4 T 細胞
  • 發展整合蛋白質體學、代謝體學和轉錄組學的多組體學物標記組，用於對愛滋病毒疾病進展進行分層

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：2025年美國關稅的累積影響

8. HIV/AIDS 診斷市場（依檢測類型）

  • 抗體檢測
    • ELISA/EIA
    • 快速檢測
    • 蛋白質印跡試驗
  • CD4偵測
  • 病毒量測試

9. HIV/AIDS 診斷市場（依產品類型）

  • 耗材和試劑
  • 設備和套件
  • 軟體
  • 測試服務

第 10 章 HIV/AIDS 診斷市場（按測試方法）

  • 實驗室檢測
  • 就地檢驗
  • 自檢

第 11 章。 HIV/AIDS 診斷市場（按最終用戶）

  • 血庫和輸血中心
  • 診斷中心
  • 居家照護環境
  • 醫院和診所
  • 研究所

第 12 章：愛滋病毒/愛滋病診斷市場（按應用）

  • 疾病進展
  • 監控
  • 篩檢

13.美國HIV/AIDS診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲愛滋病毒/愛滋病診斷市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區愛滋病毒/愛滋病診斷市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd.
    • ACON Laboratories
    • Beckman Coulter, Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories
    • bioMerieux SA
    • Chembio Diagnostics, Inc.
    • Danaher Corporation
    • DiaSorin SpA
    • ELITechGroup
    • Euroimmun Medizinische Labordiagnostika AG
    • Hologic, Inc.
    • InBios International, Inc.
    • OraSure Technologies
    • Ortho Clinical Diagnostics, Inc.
    • SD Biosensor Inc.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific, Inc.
    • Trinity Biotech plc
    • Viracor Eurofins Diagnostic Services
    • Wondfo Biotech Co. Ltd.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-437E9896A55D

The HIV or AIDS Diagnostics Market was valued at USD 2.45 billion in 2024 and is projected to grow to USD 2.60 billion in 2025, with a CAGR of 6.34%, reaching USD 3.54 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.45 billion
Estimated Year [2025] USD 2.60 billion
Forecast Year [2030] USD 3.54 billion
CAGR (%) 6.34%

How Rapid Advances and Strategic Collaboration Are Redefining HIV and AIDS Diagnostic Solutions to Enhance Early Detection and Patient Outcomes

The landscape of HIV and AIDS diagnostics has undergone remarkable transformation in recent years, driven by breakthroughs in molecular biology, digital health, and a deeper understanding of viral pathophysiology. Today's diagnostic ecosystem extends far beyond traditional laboratory settings, incorporating rapid point-of-care platforms, home self-testing solutions, and integrated data analytics that empower clinicians with real-time insights. Early and accurate detection remains the cornerstone of effective patient management, and advances such as multiplex antibody assays and next-generation viral load techniques are closing critical gaps in sensitivity and turnaround time. Furthermore, collaborations between diagnostic developers, public health institutions, and community organizations have amplified reach, ensuring that underserved populations gain equitable access to testing services.

As regulatory agencies accelerate approval pathways for novel diagnostics, there has been an influx of innovative platforms designed to streamline workflows and reduce overall testing costs. Digital connectivity features now embed seamlessly into laboratory information management systems, enabling secure, interoperable data exchange and predictive analytics for patient outcomes. In parallel, the rise of decentralized testing models, supported by portable instruments and smartphone-enabled readers, is bringing HIV diagnostics closer to the point of need. Looking forward, precision diagnostics and adaptive surveillance strategies promise to redefine how clinicians and public health leaders anticipate, monitor, and respond to the evolving HIV and AIDS epidemic.

Emerging Point-Of-Care Technologies and Integrated Care Models Are Driving Transformative Shifts in the Global HIV and AIDS Diagnostic Landscape

Innovation in HIV and AIDS diagnostics is unfolding at an unprecedented pace, catalyzed by emerging point-of-care technologies and integrated care models that address long-standing challenges in access and speed. Laboratory-based platforms continue to offer unparalleled sensitivity for viral load quantification, yet the proliferation of portable immunoassay readers and nucleic acid amplification devices is enabling clinicians to deliver same-visit results in remote settings. Meanwhile, self-testing kits are empowering individuals to engage proactively with their health, reducing stigma and expanding testing coverage in communities where traditional infrastructure may be limited.

In addition, partnerships between diagnostic manufacturers and digital health firms are producing solutions that integrate test results with electronic health records, telemedicine services, and patient support applications. These alliances are accelerating data-driven decision making, driving adherence monitoring, and facilitating linkage to care. Concurrently, regulatory frameworks are evolving to accommodate emergency use authorizations and expedited reviews, especially for diagnostics that demonstrate high clinical utility. Collectively, these trends are reshaping the diagnostic ecosystem, fostering an environment where agility, collaboration, and patient-centric design converge to elevate the standard of HIV and AIDS testing globally.

Assessing the Cumulative Impact of United States Tariffs on HIV and AIDS Diagnostic Supply Chains, Pricing Structures, and Global Market Dynamics by 2025

United States tariffs implemented in 2025 have introduced new dynamics across the HIV and AIDS diagnostic supply chain, affecting cost structures, procurement strategies, and regional partnerships. Reagents and consumables that originate from targeted regions have become subject to incremental duties, leading some suppliers to reevaluate sourcing and to consider regional manufacturing hubs. As a result, manufacturers have accelerated efforts to establish localized production facilities for critical assay components, reducing reliance on cross-border shipments and mitigating exposure to future tariff fluctuations.

These shifts have also prompted diagnostic firms to optimize their product portfolios, prioritizing assays with higher value-added features that can absorb additional costs without compromising clinical affordability. In parallel, research and development investments are focusing on alternative chemistries and modular instrument designs that facilitate in-country assembly and calibration. Even as procurement departments grapple with revised pricing models, procurement teams and policy makers are collaborating to secure volume-based agreements and to streamline customs processes.

Looking ahead, the tariff environment underscores the importance of supply chain resilience. Diagnostic companies are forging strategic alliances with regional suppliers, reinforcing distribution networks, and harnessing digital supply-chain monitoring to anticipate disruptions. Through these adaptive strategies, stakeholders are navigating the tariff landscape while preserving access to essential HIV and AIDS diagnostic services.

Unveiling Critical Market Segmentation Insights Spanning Test Types, Products, Testing Methods, End Users, and Applications in HIV and AIDS Diagnostics

A nuanced understanding of HIV and AIDS diagnostics emerges when considering the variety of test types, products, methodologies, end-user settings, and application areas that collectively define the market. Antibody tests remain fundamental, encompassing enzyme-linked immunosorbent assays, rapid immunochromatographic platforms, and confirmatory Western blot techniques, each catering to distinct operational needs and sensitivity requirements. CD4 cell enumeration and viral load quantification continue to be indispensable for disease staging and treatment monitoring, leveraging flow cytometry, PCR-based amplifiers, and innovative microfluidic approaches. In parallel, the diagnostic landscape is shaped by consumables and reagents, from specialized enzyme substrates to lyophilized PCR master mixes, alongside instruments and kits that integrate sample preparation, amplification, and detection into streamlined workflows.

Software solutions for data management, connectivity, and analytics are emerging as key differentiators, enabling laboratories to aggregate patient data, track epidemiological trends, and support telehealth initiatives. Testing services delivered through centralized laboratories coexist with onsite testing models, such as point-of-care platforms offering rapid turnaround in community clinics, and self-testing kits that empower individuals to conduct HIV screening at home. Blood banks and transfusion centers, diagnostic centers, home care settings, hospitals, clinics, and research institutes each demand tailored diagnostic capabilities, ranging from high-throughput screening to specialized immunophenotyping. Finally, the applications of HIV and AIDS diagnostics span initial screening for seroconversion, monitoring therapeutic efficacy through viral suppression metrics, and assessing disease progression via CD4 count trajectories, driving the continued diversification of assay portfolios.

Analyzing Key Regional Dynamics Shaping Growth and Innovation in HIV and AIDS Diagnostics across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics profoundly influence how HIV and AIDS diagnostics evolve, with the Americas, comprising both mature North American healthcare systems and emerging Latin American markets, demonstrating robust adoption of advanced molecular assays alongside expanded public health screening initiatives. Stakeholders in this region benefit from strong regulatory frameworks, significant R&D investments, and collaborations between government agencies and private sector laboratories, facilitating early detection campaigns and treatment monitoring programs. By contrast, Europe, the Middle East, and Africa present a diverse tapestry of needs, where high-income countries deploy next-generation sequencing for drug resistance analysis and lower-income regions leverage point-of-care and self-testing solutions to overcome infrastructure constraints and reach underserved communities.

Meanwhile, the Asia-Pacific region is witnessing rapid uptake of cost-effective immunoassays, coupled with an increasing emphasis on digital integration and telemedicine platforms. Governments across this region are investing in universal screening programs and public-private partnerships to enhance laboratory capacity and distribute testing kits to rural areas. Multinational diagnostic firms are tailoring portfolios to local regulatory requirements and price sensitivity, while domestic manufacturers are scaling production to meet regional demand. Together, these regional trends underscore the importance of context-specific strategies, where regulatory alignment, supply chain agility, and culturally sensitive outreach determine the success of diagnostic initiatives.

Profiling Leading Industry Players Driving Innovation, Partnerships, and Strategic Initiatives in the HIV and AIDS Diagnostics Sector

A cadre of leading diagnostic companies continues to shape the HIV and AIDS testing landscape, propelled by strategic acquisitions, breakthrough innovations, and expansive distribution networks. Global healthcare technology firms have fortified their portfolios through targeted collaborations with biotechnology startups specializing in rapid test development and digital connectivity solutions. These partnerships are yielding integrated platforms that combine serological, cellular, and molecular assays with cloud-based reporting, meeting the dual demands of laboratory precision and point-of-care convenience.

In response to tariff-induced supply challenges, certain firms have relocated assembly lines closer to key markets, optimizing logistical efficiency and accelerating product delivery. At the same time, a subset of diagnostics innovators is pioneering next-generation technologies-such as CRISPR-based detection systems and microarray workflows-to enable ultra-sensitive, multiplexed screening in resource-limited settings. Meanwhile, several companies are expanding their market reach through alliances with nonprofit organizations and global health initiatives, ensuring their assays are incorporated into large-scale screening and treatment programs. Collectively, these strategic moves and technological investments underscore the competitive rigor and collaborative spirit driving the industry forward.

Delivering Actionable Recommendations for Industry Leaders to Navigate Regulatory Changes, Technological Advancements, and Competitive Pressures in Diagnostics

To navigate the evolving complexities of HIV and AIDS diagnostics, industry leaders should prioritize the diversification of supply chains by forging regional manufacturing alliances and establishing contingency sourcing protocols. Embracing modular instrument designs and flexible reagent formats will enable rapid adaptation to tariff fluctuations and regulatory changes. Simultaneously, integrating artificial intelligence-driven analytics into diagnostic workflows can enhance predictive capabilities, support clinical decision making, and optimize disease surveillance efforts. Building on these technological foundations, stakeholders are encouraged to cultivate partnerships with telehealth providers and community-based organizations to extend reach and improve linkage to care following positive test results.

Investing in workforce development and training programs will ensure that healthcare professionals and laboratory technicians remain proficient in emerging diagnostic methodologies and digital platforms. Moreover, engaging proactively with policymakers can shape favorable regulatory environments for novel diagnostics, including emergency use pathways and accelerated approval mechanisms. Finally, differentiating service offerings through value-added features-such as interoperability, data security, and patient engagement modules-will distinguish organizations in a competitive marketplace and drive sustainable growth.

Outlining a Robust Research Methodology Leveraging Primary and Secondary Sources for Comprehensive Analysis of the HIV and AIDS Diagnostics Market

This research undertook a rigorous, multi-tiered methodology combining primary interviews with key opinion leaders, laboratory directors, regulatory experts, and procurement officers across major geographic regions. Secondary research encompassed a thorough review of peer-reviewed journals, technical whitepapers, patent filings, regulatory databases, and public health agency publications to capture the latest innovations and policy developments. Data were triangulated to validate trends, identify emerging applications, and reconcile discrepancies between proprietary and open-source information.

Quantitative analyses were conducted using anonymized datasets from leading diagnostic manufacturers and service providers, while qualitative insights were gathered through structured discussions with healthcare practitioners and patient advocacy groups. The research framework also integrated comparative case studies of high-impact implementation projects, highlighting best practices in deployment, training, and quality assurance. Finally, findings were subjected to expert peer review to ensure accuracy, relevance, and strategic applicability for stakeholders across the HIV and AIDS diagnostics ecosystem.

Summarizing Core Findings and Strategic Implications to Guide Stakeholders in the Evolving HIV and AIDS Diagnostics Ecosystem

In conclusion, the HIV and AIDS diagnostics sector is at a pivotal juncture, characterized by accelerating technological innovation, shifting regulatory landscapes, and heightened emphasis on decentralizing testing. The interplay of advanced point-of-care platforms, digital health integrations, and modular reagents is redefining clinical pathways and empowering patients with timely, actionable results. Regional nuances-driven by infrastructure maturity, policy frameworks, and public-private collaborations-underscore the need for tailored strategies that address both high-volume screening demands and specialized monitoring requirements.

As tariff regimes introduce new considerations for supply chain resilience and cost management, diagnostic organizations must remain agile, investing in local production capabilities and strategic partnerships. By aligning product development roadmaps with emerging digital tools and evolving care models, stakeholders can enhance diagnostic reach, improve patient outcomes, and sustain competitive differentiation. Ultimately, the synthesis of these trends presents an opportunity for the industry to chart a course toward more accessible, efficient, and patient-centric HIV and AIDS diagnostic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of point-of-care HIV self-testing kits with mobile health apps to improve patient linkage to care
  • 5.2. Adoption of CRISPR-based diagnostics for rapid ultra-sensitive HIV viral load quantification in decentralized settings
  • 5.3. Impact of fourth generation combination antigen antibody assays on early acute HIV infection detection
  • 5.4. Expansion of multiplex PCR panels enabling simultaneous detection of HIV hepatitis C and tuberculosis co-infection in a single assay
  • 5.5. Emerging use of AI powered image analysis in flow cytometry for automated CD4 T cell enumeration in HIV monitoring
  • 5.6. Development of multi omics biomarker panels integrating proteomics metabolomics and transcriptomics for HIV disease progression stratification

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. HIV or AIDS Diagnostics Market, by Test Type

  • 8.1. Introduction
  • 8.2. Antibody Tests
    • 8.2.1. ELISA/EIA
    • 8.2.2. Rapid Tests
    • 8.2.3. Western Blot Test
  • 8.3. CD4 Tests
  • 8.4. Viral Load Tests

9. HIV or AIDS Diagnostics Market, by Type of Product

  • 9.1. Introduction
  • 9.2. Consumables & Reagents
  • 9.3. Instruments & Kits
  • 9.4. Software
  • 9.5. Testing Services

10. HIV or AIDS Diagnostics Market, by Testing Method

  • 10.1. Introduction
  • 10.2. Laboratory-Based Testing
  • 10.3. Point-Of-Care Testing
  • 10.4. Self-Testing

11. HIV or AIDS Diagnostics Market, by End-User

  • 11.1. Introduction
  • 11.2. Blood Banks & Transfusion Centers
  • 11.3. Diagnostic Centers
  • 11.4. Home Care Settings
  • 11.5. Hospitals & Clinics
  • 11.6. Research Institutes

12. HIV or AIDS Diagnostics Market, by Application

  • 12.1. Introduction
  • 12.2. Disease Progression
  • 12.3. Monitoring
  • 12.4. Screening

13. Americas HIV or AIDS Diagnostics Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa HIV or AIDS Diagnostics Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific HIV or AIDS Diagnostics Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. F. Hoffmann-La Roche Ltd.
    • 16.3.3. ACON Laboratories
    • 16.3.4. Beckman Coulter, Inc.
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. Bio-Rad Laboratories
    • 16.3.7. bioMerieux SA
    • 16.3.8. Chembio Diagnostics, Inc.
    • 16.3.9. Danaher Corporation
    • 16.3.10. DiaSorin S.p.A.
    • 16.3.11. ELITechGroup
    • 16.3.12. Euroimmun Medizinische Labordiagnostika AG
    • 16.3.13. Hologic, Inc.
    • 16.3.14. InBios International, Inc.
    • 16.3.15. OraSure Technologies
    • 16.3.16. Ortho Clinical Diagnostics, Inc.
    • 16.3.17. SD Biosensor Inc.
    • 16.3.18. Siemens Healthineers AG
    • 16.3.19. Thermo Fisher Scientific, Inc.
    • 16.3.20. Trinity Biotech plc
    • 16.3.21. Viracor Eurofins Diagnostic Services
    • 16.3.22. Wondfo Biotech Co. Ltd.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. HIV OR AIDS DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. HIV OR AIDS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. HIV OR AIDS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. HIV OR AIDS DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 26. HIV OR AIDS DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. HIV OR AIDS DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 28. HIV OR AIDS DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. HIV OR AIDS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ELISA/EIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ELISA/EIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CD4 TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CD4 TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY VIRAL LOAD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY VIRAL LOAD TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY LABORATORY-BASED TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY LABORATORY-BASED TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SELF-TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SELF-TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY BLOOD BANKS & TRANSFUSION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY BLOOD BANKS & TRANSFUSION CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DISEASE PROGRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DISEASE PROGRESSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 84. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 93. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 94. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 95. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 96. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 97. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 98. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 99. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 100. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 103. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 106. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 107. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 108. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 109. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 110. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 113. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 114. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 115. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 118. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 119. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 120. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 121. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 122. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 123. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 124. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 125. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 127. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 130. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 131. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 132. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 133. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 134. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 135. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 136. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 137. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 138. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 165. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 168. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 169. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 171. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 172. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 173. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 174. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 175. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 177. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 180. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 181. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 183. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 184. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 185. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 186. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 187. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 189. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 192. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 193. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 195. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 196. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 197. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 198. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 199. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 201. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 204. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 205. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 207. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 208. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 209. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 210. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 211. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 216. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 217. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 219. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 220. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 221. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 222. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 223. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 240. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 242. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 244. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 252. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 256. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 257. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 259. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 261. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 264. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 265. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 266. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 267. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 268. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 269. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 270. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 271. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 276. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 280. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 282. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 285. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 288. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 289. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 290. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 291. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 292. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 293. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 294. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 295. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 297. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 300. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 301. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 302. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 303. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 304. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 305. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 306. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 307. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 309. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 312. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 313. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 314. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 315. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 316. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 317. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 318. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 319. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 321. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 324. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 325. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 326. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 327. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 328. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD M